A statement released earlier today by H.C. Wainwright about Aldeyra Therapeutics (NASDAQ:ALDX) ups the target price to $18.00
- Updated: September 25, 2016
Boasting a price of $7.45, Aldeyra Therapeutics (NASDAQ:ALDX) traded 1.36% higher on the day. The last close is up 32.88% from the 200-day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time. The company has recorded a 50-day moving average of $5.93 and a 200-day moving average of $5.61. 97,236 shares of the stock were exchanged, up from an average trading volume of 51,889
In a report issued 9/26/2016 H.C. Wainwright bumped up the target of Aldeyra Therapeutics (NASDAQ:ALDX) to $18.00 reporting a potential upside of 1.42%.
Previously on 07/01/2015, Canaccord Genuity reported about Aldeyra Therapeutics (NASDAQ:ALDX) upped the target price from $0.00 to $16.00 that suggested an upside of 0%.
See Chart Below
Aldeyra Therapeutics has a with a one year low of $3.39 and a 52 week high of $7.70 Aldeyra Therapeutics’s market cap is currently $0.
About Aldeyra Therapeutics (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.